Key result
Increased epicardial adipose tissue volume and lower density are linked to worse cardiometabolic outcomes.
Why the study?
Correlations between obesity and chronic metabolic and cardiovascular diseases have highlighted the pro-inflammatory role of epicardial adipose tissue, but an update is needed on how imaging-based EAT assessment relates to comorbidities and patient prognosis.
Systematic Review (n=10,458)
Quantification of epicardial adipose tissue via standard imaging may improve the non-invasive assessment of patient cardiometabolic risk and aid in monitoring therapeutic efficacy.
The observation of correlations between obesity and chronic metabolic and cardiovascular diseases has led to the emergence of strong interests in "adipocyte biology", in particular in relation to a specific visceral adipose tissue that is the epicardial adipose tissue (EAT) and its pro-inflammatory role. In recent years, different imaging techniques frequently used in daily clinical practice have tried to obtain an EAT quantification. We provide a useful update on comorbidities related to chronic inflammation typical of cardiac adiposity, analyzing how the EAT assessment could impact and provide data on the patient prognosis. We assessed for eligibility 50 papers, with a total of 10,458 patients focusing the review on the evaluation of EAT in two main contexts: cardiovascular and metabolic diseases. Given its peculiar properties and rapid responsiveness, EAT could act as a marker to investigate the basal risk factor and follow-up conditions. In the future, EAT could represent a therapeutic target for new medications. The assessment of EAT should become part of clinical practice to help clinicians to identify patients at greater risk of developing cardiovascular and/or metabolic diseases and to provide information on their clinical and therapeutic outcomes.
No takes yet. Share an insight, caveat, or question.
Tarsitano et al. (2022) conducted a systematic review in Cardiovascular and metabolic diseases (n=10,458). Epicardial adipose tissue (EAT) assessment was evaluated on Correlation of EAT with cardiovascular and metabolic disease prognosis. Epicardial adipose tissue acts as an imaging biomarker for cardiometabolic risk, with increased volume and decreased density associated with adverse cardiovascular and metabolic outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: